Goldman Sachs Group Inc Vertex Pharmaceuticals Inc Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,401,734 shares of VRTX stock, worth $679 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
1,401,734
Previous 1,358,534
3.18%
Holding current value
$679 Million
Previous $632 Million
10.66%
% of portfolio
0.09%
Previous 0.1%
Shares
20 transactions
Others Institutions Holding VRTX
# of Institutions
1,753Shares Held
227MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.7 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.3 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.3 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.8 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.05 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $124B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...